drugset / Trial / NCT03102190

Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps

NCT03102190

Phase 1 Terminated 6 enrolled Benjamin Bleier
SequentialOpen-labelTreatment

Summary

Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by eosinophilic inflammation as well as P-gp overexpression. A previous trial of oral Verapamil showed preliminary efficacy for the treatment of CRSwNP. The goal of this study is to evaluate the safety and efficacy of intranasal Verapamil in CRSwNP. The study was initially approved as a Phase Ib/II, but only the Phase Ib portion was completed as part of this protocol.

Timeline

Start
2017-06-05
Primary completion
2018-03-26
Completion
2018-03-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Verapamil Other / unclassified 10 mg Intranasal
Subject Verapamil Other / unclassified 20 mg Intranasal
Subject Verapamil Other / unclassified 40 mg Intranasal
Subject Verapamil Other / unclassified 80 mg Intranasal
Subject Verapamil Other / unclassified 120 mg Intranasal